Alimta

... PharmaLive: US Oncology Research Network Presents Clinical Studies at ASCO Gastrointestinal Cancers Symposium REGISTERED USERS TODAY ON PHARMALIVE.COM US Oncology Research Network Presents Clinical Studies at ASCO Gastrointestinal Cancers Symposium Clinical Studies to Show Results of Phase II Trials for Treatment of Hepatoma and Pancreatic Cancer HOUSTON, January 30, 2006 /PRNewswire/ - Leading cancer researchers affiliated with the US Oncology Research Network presented findings from a Phase II clinical study testing single agent pemetrexed in patients with advanced and metastatic hepatoma (primary liver cancer), and a phase II clinical study testing gemcitabine plus zoledronic acid on subjects with Stage IV pancreatic cancer.

The findings were presented at the 2006 Gastrointestinal Cancers Symposium Jan.

26-28 in San Francisco by physicians affiliated with US Oncology, Inc., one of the nation's largest health care services networks focused exclusively on cancer treatment and research.

"We are pleased to announce the findings of this research at this important conference," said Dr.

Thomas Cartwright of Ocala Oncology, an affiliate of US Oncology, Inc.

"Every opportunity we have to present our research and discuss our efforts with other experts in the field is an opportunity to advance the science of cancer research." The presentations included: Single-agent pemetrexed in patients with advanced and metastatic hepatoma Researchers: Allen L.

Cohn, M.D., Rocky Mountain Can...

... Philadelphia Inquirer Why Lilly seems gilded Subscriber Services Complete Forecast Search Recent News Archives Web for Philly.com Today's Inquirer Today's Daily News Front Page US & World Local & Regional Pennsylvania Shop Local Stores All Classifieds Dating Back to Home > Sunday, Jan 29, 2006 email this print this Posted on Sun, Jan.

29, 2006 W...

... cantonrep.com HOME CLASSIFIEDS JOBS REAL ESTATE AUTO COMMUNITY CALENDAR MAKE PAYMENT CLEAR21ºF weather sponsored by Search Local Obituaries Sports Lifestyle Financial Offbeat Ohio Opinion Entertainment News Elsewhere Rep Columnists Lottery Photo Gallery Newspaper Info Subscribe Advertise Registered Users E-mail Password Non-Registered Users Click Here Lost Password?

Comment on this story.Eli Lilly’s vital signs are good, but skeptics remainFriday, January 27, 2006 By THERESA AGOVINO AP Business Writer NEW YORK (AP) — Eli Lilly and Co.

has been largely immune from many of the woes bedeviling the pharmaceutical industry, and the company’s chief executive can tick off the reasons why.

Lilly avoided mergers, embraced the biotech revolution early, partnered with smaller companies and pours a larger than average percentage of revenues back into research, said chairman and CEO Sidney Taurel.

The result: Lilly introduced nine new drugs in the last four years, the pipeline holds additional promising drugs and no significant patent expirations are imminent.

And the company recently hasn’t had to withdraw a product or launch a major restructuring to shore up earnings like some of its brethren.

“I think history is proving us right if you look at our stock price,” said Taurel, looking confident and relaxed as he sat in the lobby of a Manhattan hotel.

Late last year, Indianapolis-based Lilly said its estimates for 2006 were above Wall Street’s...